Barchart.com
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
xCruzo Brief
Defence Therapeutics says it’s expanding its Accum platform radiopharmaceutical development to evaluate both alpha- and beta-emitting radioisotopes. In an announcement dated August 31, 2026, the Montreal-based company (CSE: DTC; OTCQB: DTCFF; FSE: DTC) said the move is meant to broaden Accum’s capability for intracellular transport, improving delivery of payloads into cancer cells. The program will compare alpha emitters, including Actinium-225, for high-energy, short-range damage, and beta emitters like Lutetium-177 for medium-energy, longer-range penetration. Defence aims to generate comparative pharmacology, efficacy, and safety data using preclinical work to advance Accum-enabled radio-immunoconjugates toward clinical development.
xCruzo quick-read summary • Source: Barchart.com • Read the full article for complete information.
xCruzo
Readers sound off on Brooklyn Democrats, Trump's 9/11 snub and terminal illness
Necesitas café todo el día para volver a la rutina, una nutricionista explica qué puede estar fallando
Moses Itauma Released From Hospital, Issues First Statement After Filip Hrgovic Loss
Keegan Vandermeer Scores 9-Second KO at BKB 58 in Miami - Highlights Inside
Gen Z Has 10 Everyday Stressors That Older Generations Didn't Have To Face Until Way Later In Life
El homenaje más especial a Blanca Fernández Ochoa 7 años después: su familia recorre la ruta que hizo antes de morir
PlayStation le espera un mes complicado, y no será solo por el lanzamiento de Lobezno
Saltar a Palacio Nacional - El Heraldo de México